India Pharma Outlook Team | Wednesday, 14 January 2026
Eli Lilly and Company announced today a major partnership with NVIDIA to launch a first-of-its-kind AI co-innovation lab designed to take on some of the pharmaceutical industry’s hardest problems.
The collaboration will see the two companies invest up to $1 billion over five years in talent, computing power, and infrastructure.
The new lab, located in the San Francisco Bay Area, will bring Lilly biologists, scientists, and medical experts together with NVIDIA AI researchers and engineers. Working side by side, the teams will generate massive datasets and develop advanced AI models on NVIDIA BioNeMo to sharply reduce the time it takes to discover and develop new medicines.
Also Read: Advancing Interventional Radiology in India Through Collaboration
“AI is transforming every industry, and its most profound impact will be in life sciences,” said Jensen Huang, founder and CEO of NVIDIA. “NVIDIA and Lilly are bringing together the best of our industries to invent a new blueprint for drug discovery — one where scientists can explore vast biological and chemical spaces in silico before a single molecule is made.”
“For nearly 150 years, we’ve been working to bring life-changing medicines to patients,” said David A Ricks, chair and CEO of Lilly. “Combining our volume of data and scientific knowledge with NVIDIA’s computational power and model-building expertise could reinvent drug discovery as we know it. By bringing together world-class talent in a startup environment, we’re creating the conditions for breakthroughs that neither company could achieve alone.”
The Eli Lilly–NVIDIA AI lab will focus on linking physical wet labs with AI-driven dry labs in a continuous learning loop. Built on Lilly’s AI supercomputer and next-generation NVIDIA platforms, the effort will also expand AI use across manufacturing, clinical development, and supply chains.
.jpg)
.jpg)
